# Adult Diabetic Ketoacidosis

Adult diabetic ketoacidosis requires immediate recognition of insulin deficiency, volume depletion, electrolyte derangement, and its precipitant. This review focuses on rapid diagnostic confirmation, diabetes-type reassessment, safe insulin-dependent care, and prevention of recurrent hyperglycemic crises using currently supplied evidence.

**Clinical question:** How should clinicians recognize diabetic ketoacidosis, clarify diabetes type, and prevent recurrent hyperglycemic crises in adults?

Updated: 2026-08-20T23:34:07.251543Z

## What matters in practice
- In an adult with classic hyperglycemic symptoms or hyperglycemic crisis, random plasma glucose of at least 200 mg/dL establishes diabetes; DKA requires urgent treatment and evaluation of the underlying diabetes type. [17]
- Do not assume an adult has type 2 diabetes because of age or adiposity: type 1 diabetes occurs at all ages, and adult misclassification is common. [17]
- Younger age, lower BMI, unintentional weight loss, ketoacidosis, and marked hyperglycemia favor type 1 diabetes; GAD antibody testing followed by IA-2 and/or ZnT8 testing can support classification when phenotype overlaps. [17]
- C-peptide helps classify insulin-treated adults when diabetes type remains uncertain, but should not be tested within 2 weeks after a hyperglycemic emergency. [17]
- Patients with type 1 diabetes require uninterrupted basal insulin during acute illness, hospitalization, fasting, and procedures because withholding insulin risks ketosis and DKA. [14]

## Treat suspected DKA as an insulin-deficient emergency

DKA should trigger simultaneous stabilization, biochemical assessment, and cause-directed evaluation.

DKA reflects clinically consequential insulin deficiency with hyperglycemia, ketonemia, dehydration, acidemia, and electrolyte disturbance. It is classically associated with type 1 diabetes but can occur in insulinopenic type 2 diabetes, ketosis-prone type 2 diabetes, acute illness, missed insulin, and sodium-glucose cotransporter 2 inhibitor exposure. [17]

The supplied sources do not provide a complete adult DKA fluid, insulin infusion, potassium replacement, bicarbonate, or transition-to-subcutaneous-insulin protocol. Therefore, institutionally approved hyperglycemic-crisis pathways and current specialty guidance should govern acute resuscitation and monitoring rather than extrapolation from the diabetes-management sources reviewed here. [17]
- Obtain plasma glucose and assess for hyperglycemic crisis; a random plasma glucose of at least 200 mg/dL with classic hyperglycemic symptoms or crisis meets diagnostic criteria for diabetes. [17]
- Obtain A1C when clinically useful to estimate antecedent glycemia; it does not replace acute glucose-based assessment in a hyperglycemic crisis. [17]
- Identify likely precipitants, including insulin interruption, infection or other acute illness, myocardial infarction, glucocorticoids, second-generation antipsychotics, and SGLT2 inhibitor use. [17]
- Document diabetes type and home insulin regimen early; in established type 1 diabetes, basal insulin must not be interrupted. [14]

*Clinical classification issues that change management after DKA resolution. [17]*

| Finding | Clinical implication | Next action |
| --- | --- | --- |
| Classic hyperglycemic symptoms or hyperglycemic crisis with random plasma glucose ≥200 mg/dL | Diabetes is established clinically. [17] | Treat the crisis and determine whether the patient has absolute or relative insulin deficiency. [17] |
| Adult with weight loss, ketoacidosis, marked hyperglycemia, younger age, or low BMI | Features favor autoimmune type 1 diabetes but no single feature is definitive. [17] | Order GAD antibody; if negative and suspicion remains, add IA-2 and/or ZnT8 antibodies where available. [17] |
| Insulin-treated adult with persistent uncertainty about diabetes type | C-peptide may clarify endogenous insulin secretion. [17] | Use a random C-peptide with concurrent glucose within 5 hours of eating; avoid testing within 2 weeks after a hyperglycemic emergency. [17] |
| Obesity or metabolic syndrome with DKA | Does not exclude type 1 diabetes; ketosis-prone type 2 diabetes is also possible. [17] | Maintain insulin until classification and insulin requirement are clear. [17] |

## Reassess diabetes type after initial stabilization

Misclassification can produce unsafe insulin withdrawal or delayed insulin initiation.

Diabetes classification is often uncertain at presentation. Type 1 diabetes can occur at any age, obesity does not exclude autoimmune diabetes, and approximately 40% of adults with newly diagnosed type 1 diabetes may initially be misdiagnosed as having type 2 diabetes. [17]

The most useful clinical features favoring type 1 diabetes are age younger than 35 years, BMI below 25 kg/m2, unintentional weight loss, ketoacidosis, and plasma glucose above 360 mg/dL at presentation. Family history, ketosis without acidosis, osmotic symptoms, and coexisting autoimmune disease are weaker discriminators. [17]

For adults with overlapping phenotypic features, standardized islet autoantibody testing is recommended. GAD is the preferred first test; if negative, IA-2 and/or ZnT8 antibodies should be considered where available. A negative antibody test does not exclude type 1 diabetes. [17]
- Consider pancreatic diabetes in patients with acute or chronic pancreatitis, pancreatic surgery, pancreatic neoplasia, or exocrine pancreatic insufficiency; these patients may have loss of both insulin and glucagon secretion. [17]
- Consider monogenic diabetes when diabetes begins in the first 6 months of life, when early-onset diabetes follows an autosomal dominant pattern, or when phenotype is atypical for type 1 and type 2 diabetes. [17]
- In adults with suspected type 1 diabetes who are not receiving insulin, provide close monitoring and education so insulin can be started promptly if glycemia deteriorates. [17]

*Interpretation of C-peptide in insulin-treated adults with uncertain diabetes classification. [17]*

| Result or circumstance | Interpretation | Action |
| --- | --- | --- |
| Random C-peptide ≥600 pmol/L (≥1.8 ng/mL) | Substantial endogenous insulin secretion; testing circumstances are less consequential. [17] | Assess for type 2 diabetes, monogenic diabetes, or other nonautoimmune diabetes while integrating phenotype and autoantibody results. [17] |
| Random C-peptide <80 pmol/L (<0.24 ng/mL) | Very low endogenous insulin secretion. [17] | Treat as severe insulin deficiency; do not discontinue insulin. [17] |
| C-peptide 200–600 pmol/L (0.6–1.8 ng/mL) | Usually consistent with type 1 diabetes or MODY, but may occur in insulin-treated type 2 diabetes. [17] | Interpret with concurrent glucose, duration of diabetes, phenotype, and antibody testing. [17] |
| Within 2 weeks of hyperglycemic emergency | Result may not be appropriate for classification. [17] | Defer C-peptide testing until recovery. [17] |

## Protect against recurrent ketosis during transitions of care

Insulin omission is a preventable driver of recurrent DKA in insulin-deficient diabetes.

For people with type 1 diabetes, uninterrupted basal insulin is essential to prevent hyperglycemia and ketoacidosis during hospitalization, fasting, and procedures. This requirement should be explicit in admission orders, perioperative plans, and handoffs. [14]

Inpatient self-management may be appropriate only for selected patients who can safely administer insulin, monitor glucose, count carbohydrates, and participate in decisions under supervision from clinicians knowledgeable in glycemic management. [14]

Hyperglycemia with DKA can also arise in type 2 diabetes during severe illness, insulin omission, or exposure to drugs including SGLT2 inhibitors. Because SGLT2 inhibitors can be associated with DKA, review these agents during every DKA evaluation. [17]
- Before stopping intravenous insulin or changing treatment intensity, verify that the patient has a viable subcutaneous insulin plan, access to insulin and supplies, and education on deterioration and ketone-risk symptoms; supplied sources support the need for uninterrupted basal insulin in type 1 diabetes but do not specify transition timing or dosing. [14]
- If a personal insulin pump is used, unexplained persistent hyperglycemia should prompt assessment for infusion interruption or site failure; if glucose does not improve after a correction, use injected insulin and change the infusion site. [14]
- Consider social and financial barriers to insulin, food, transportation, monitoring supplies, and follow-up. These barriers can impair self-management and increase acute complication risk. [14]

## Use follow-up to prevent the next hyperglycemic crisis

Recurrent DKA prevention depends on insulin access, skills, monitoring, and timely phenotype clarification.

Diabetes self-management education and support is a core element of diabetes care. CDC guidance emphasizes ongoing team-based support and notes that structured diabetes self-management education and support is associated with lower A1C and fewer complications. [22]

A1C monitoring frequency should reflect stability of therapy and glycemic control. CDC advises testing every 3 months when treatment has changed or goals are not met and every 6 months when treatment and glycemic goals are stable. [13]

For type 2 diabetes treated with metformin plus an SGLT2 inhibitor or GLP-1 agonist, ACP states that routine self-monitoring of blood glucose may be unnecessary in stable patients; this does not apply to insulin-dependent patients or those at risk for hypoglycemia or recurrent ketosis. [2]
- At post-DKA review, reconcile all insulin products, injection or pump technique, access to glucose and ketone monitoring, and prescription affordability. [14]
- Review sick-day and device-failure plans, including when to seek urgent care for persistent hyperglycemia, vomiting, dehydration, or suspected ketosis; the sources establish these as clinically relevant risks but do not specify a universal outpatient ketone threshold. [14]
- Screen for psychosocial distress, depression, and barriers to care, especially after recurrent DKA or medication rationing. [14]
- For adults with type 2 diabetes and inadequate control despite metformin and lifestyle measures, ACP recommends adding either an SGLT2 inhibitor or GLP-1 agonist; choose SGLT2 inhibitors preferentially with heart failure or chronic kidney disease and GLP-1 agonists when stroke risk or weight loss is a major priority. [2]

## What the supplied evidence does not support

Avoid false precision when source material does not contain acute-care protocol details.

The provided search results include current diabetes diagnostic and classification guidance, longitudinal type 1 diabetes management, and general diabetes-care resources, but do not include a dedicated adult DKA consensus guideline or FDA labeling for insulin and adjunctive agents. Accordingly, they do not support publishing exact intravenous fluid choice or rate, insulin infusion dose, potassium replacement thresholds, bicarbonate criteria, phosphate therapy, anion-gap transition criteria, or ICU disposition thresholds. [14][17]

Acute DKA care should therefore follow a current, locally adopted adult hyperglycemic-crisis protocol with endocrine and critical-care consultation as appropriate. Diabetes classification and recurrent-crisis prevention should proceed in parallel with acute stabilization. [14][17]

## Common questions

### Can an adult with obesity and DKA still have type 1 diabetes?

Yes. Obesity does not exclude type 1 diabetes. In adults with DKA or an overlapping phenotype, evaluate clinical features, islet autoantibodies, and—after recovery when appropriate—C-peptide before reducing or discontinuing insulin. [17]

### When should C-peptide be measured after DKA?

Do not measure C-peptide within 2 weeks of a hyperglycemic emergency. In insulin-treated patients with uncertain diabetes type, a random sample with concurrent glucose within 5 hours of eating can help classify endogenous insulin secretion after recovery. [17]

### Should basal insulin be held when an adult with type 1 diabetes is fasting or hospitalized?

No. Type 1 diabetes requires uninterrupted basal insulin to prevent hyperglycemia and ketoacidosis, including during hospitalization, fasting, and procedures. [14]

### What diabetes medications should be reviewed in every DKA presentation?

Review all insulin access and adherence, recent glucocorticoids or second-generation antipsychotics, and SGLT2 inhibitor exposure. DKA can occur in insulinopenic type 2 diabetes and has been associated with SGLT2 inhibitor use. [17]

## References
1. Drug Dosing Recommendations for All Patients: A Roadmap ... — ascpt.onlinelibrary.wiley.com — https://ascpt.onlinelibrary.wiley.com/doi/10.1002/cpt.1923
2. Newer Pharmacologic Treatments in Adults With Type 2 Diabetes: A Clinical Guideline From the American College of Physicians — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC11614146
3. Newer Pharmacologic Treatments in Adults With Type 2 Diabetes: A Clinical Guideline From the American College of Physicians - PubMed — pubmed.ncbi.nlm.nih.gov — https://pubmed.ncbi.nlm.nih.gov/38639546
4. Quality of Care in Adults With Diabetes - Diabetes in America - NCBI Bookshelf — www.ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/books/NBK612584
5. A review of the quality of current diabetes clinical practice guidelines - PMC — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC6645402
6. Recent Updates to Clinical Practice Guidelines for Diabetes ... — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC8901964
7. Introduction and Methodology: Standards of Care in Diabetes—2026 - PMC — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC12690168
8. Type 2 diabetes in adults: management - NCBI Bookshelf — www.ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/books/NBK553486
9. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY COMPREHENSIVE CLINICAL PRACTICE GUIDELINES FOR MEDICAL CARE OF PATIENTS WITH OBESITY - PubMed — pubmed.ncbi.nlm.nih.gov — https://pubmed.ncbi.nlm.nih.gov/27219496
10. 6. Glycemic Goals and Hypoglycemia: Standards of Care in ... — www.ccjm.org — https://www.ccjm.org/lookup/external-ref?access_num=10.2337%2Fdc25-S006&link_type=DOI
11. 16. Diabetes Care in the Hospital: Standards of Care in ... — www.ccjm.org — https://www.ccjm.org/lookup/external-ref?access_num=10.2337%2Fdc24-S016&link_type=DOI
12. Diabetes - StatPearls - NCBI Bookshelf — www.ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/books/NBK551501
13. Your Diabetes Care Schedule — www.cdc.gov — https://www.cdc.gov/diabetes/treatment/your-diabetes-care-schedule.html
14. The Management of Type 1 Diabetes - Endotext - NCBI - NIH — www.ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/books/NBK279114
15. 2. Classification and Diagnosis of Diabetes: Standards of ... — diabetesjournals.org — https://diabetesjournals.org/care/article/45/Supplement_1/S17/138925/2-Classification-and-Diagnosis-of-Diabetes
16. Diagnosis and Classification of Diabetes Mellitus — diabetesjournals.org — https://diabetesjournals.org/care/article/37/Supplement_1/S81/37753/Diagnosis-and-Classification-of-Diabetes-Mellitus
17. 2. Diagnosis and Classification of Diabetes: Standards of Care ... — diabetesjournals.org — https://diabetesjournals.org/care/article/48/Supplement_1/S27/157566/2-Diagnosis-and-Classification-of-Diabetes
18. 2. Classification and Diagnosis of Diabetes — diabetesjournals.org — https://diabetesjournals.org/care/article/40/Supplement_1/S11/36898/2-Classification-and-Diagnosis-of-Diabetes
19. NCT00081328 | Treatment Options for Type 2 Diabetes in ... — clinicaltrials.gov — https://clinicaltrials.gov/study/NCT00081328
20. Type 2 diabetes in adults: management | Guidance — www.nice.org.uk — https://www.nice.org.uk/guidance/ng28
21. Overview | Type 1 diabetes in adults: diagnosis and management  | Guidance | NICE — www.nice.org.uk — https://www.nice.org.uk/guidance/ng17
22. Clinical Guidance for Diabetes — www.cdc.gov — https://www.cdc.gov/diabetes/hcp/clinical-guidance/index.html
23. Management of Diabetes — www.who.int — https://www.who.int/southeastasia/activities/management-of-diabetes
24. Considerations for Blood Glucose Monitoring and Insulin Administration | Injection Safety | CDC — www.cdc.gov — https://www.cdc.gov/injection-safety/hcp/infection-control/index.html

## Editorial note

Prepared from cited clinical literature using Astra's research workflow. Verify recommendations against current guidance and patient-specific factors.